A5068258885- Lung Cancer Treatments and Mutations
- COVID-19 and healthcare impacts
- Hepatocellular Carcinoma Treatment and Prognosis
- Venous Thromboembolism Diagnosis and Management
- Lymphoma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- RNA Interference and Gene Delivery
- COVID-19 Clinical Research Studies
- Cancer Mechanisms and Therapy
- COVID-19 Impact on Reproduction
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Uterine Myomas and Treatments
- HER2/EGFR in Cancer Research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Ferroptosis and cancer prognosis
- Viral-associated cancers and disorders
- Cutaneous lymphoproliferative disorders research
- DNA Repair Mechanisms
- Telomeres, Telomerase, and Senescence
- DNA and Nucleic Acid Chemistry
- Wnt/β-catenin signaling in development and cancer
- Chronic Lymphocytic Leukemia Research
- Immune responses and vaccinations
- Extracellular vesicles in disease
University of Michigan
2019-2024
Illinois College
2014-2020
University of Illinois Chicago, Rockford campus
2015-2020
University of Illinois Chicago
2013-2016
Rockford University
2014
<h3>Importance</h3> Non-Hispanic Black individuals experience a higher burden of COVID-19 than the general population; hence, there is an urgent need to characterize unique clinical course and outcomes in patients with cancer. <h3>Objective</h3> To investigate racial disparities severity presentation, complications, between non-Hispanic White cancer COVID-19. <h3>Design, Setting, Participants</h3> This retrospective cohort study used data from Cancer Consortium registry March 17, 2020,...
Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims elucidate this mechanism TKI resistance by investigating key mTOR and Wnt signaling proteins melanoma cell lines resistant SU11274, a TKI. Xenografts from RU cells treated with TKIs SU11274 JNJ38877605 showed 7- 6-fold reduction tumor size, respectively. Resistant displayed upregulation...
Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis treatment are well-known risk factors; however, a assessment model (RAM) for VTE in both is lacking. To assess the incidence factors thrombosis hospitalized COVID-19. Among Cancer Consortium registry (CCC19) cohort study, we assessed ATE within 90 days COVID-19-associated hospitalization. A multivariable logistic regression specifically was built using priori...
Background: Experimental disruption of the telomere overhang induces a potent DNA damage response and is target newly emerging cancer therapeutics. Introduction T-oligo, an eleven-base oligonucleotide homologous to 3'-telomeric overhang, mimics responses through activation p53, p73, p95/Nbs1, E2F1, pRb, other proteins. ATM (ataxia telangiectasia mutated) was once thought be primary driver T-oligo-induced responses; however, recent experiments have highlighted key proteins that may also play...
Background: EGFR/c-Met activation/amplification and co-expression, mTOR upregulation/activation, Akt/Wnt signaling upregulation have been individually associated with more aggressive disease characterized as potential prognostic markers for lung cancer patients. Methods: Tumors obtained from 109 participants stage I–IV non-small cell (NSCLC) were studied co-localization well total active forms of EGFR, c-Met, mTOR, S6K, beta-catenin, Axin2. Slides graded by two independent blinded...
Abstract: Mantle cell lymphoma (MCL) is an incurable intermediate-grade representing 5–6% of non-Hodgkin's lymphomas diagnosed in the United States. The introduction inhibitors Bruton's tyrosine kinase (BTK) into targeted therapy for MCL has significantly improved outcomes patients with relapsed/refractory (R/R) disease. Since initial approval first-generation inhibitor, ibrutinib, several second-generation have been explored. Acalabrutinib, a BTK demonstrated impressive efficacy clinical...
While thrombosis and pregnancy loss are the best-known clinical features of antiphospholipid syndrome (APS), many patients also exhibit "extra-criteria" manifestations, such as thrombocytopenia. The mechanisms that drive APS thrombocytopenia not completely understood, no biomarkers available for predicting antibody (aPL)-mediated Calprotectin is a heterodimer S100A8 S100A9 abundant in neutrophil cytoplasm released upon proinflammatory activation. Here, we sought to evaluate presence,...
Abstract Current EGFR/c-Met tyrosine kinase inhibitor (TKI) combination therapies are shown to be susceptible acquired resistance in the majority of NSCLC patients. To understand how cells develop TKI resistance, we use three model cell lines: H2170, H358 and H1975. H2170 lines express high levels EGFR c-Met wild-type. These were made resistant erlotinib, SU11274 a both by exposure increasing concentrations these TKIs. The H1975 line is positive for two TKD mutations (T790M L858R) which...
e18788 Background: Patients (pts) with cancer have a high risk of venous thromboembolic (VTE) complications, further enhanced by anti-cancer treatments, specifically hormonal therapies, targeted therapies (VEGF inhibitors, other TKIs) and immune checkpoint inhibitors (ICIs). We hypothesized that high-risk would predispose pts COVID-19 to higher VTE complications. Methods: CCC19 is the largest international registry (NCT04354701) recording outcomes COVID-19. The was queried for hospitalized...
Abstract NSCLC tumors acquire resistance to EGFR-TKIs, and studies have suggested that co-localization of c-MET EGFR may be a modality acquired resistance. Upregulation alternative signaling pathways such as Wnt or mTOR been shown associated with poor prognosis are potential mechanism This study aims at examining these EGFR/c-MET co-expression in 100 patients stage I-IV NSCLC. We data on 50 patients, working the remaining samples. Tumor tissue from biopsies resections obtained IRB approval,...
Abstract Lung cancer is projected to be the number one cause of mortality in United States 2014. Therapies such as tyrosine kinase inhibitors (TKIs) have been developed treat non-small cell lung (NSCLC), which accounts for 80-85% all cases. EGFR a protein that often targeted by these TKIs and several EGFR-TKIs approved clinical use. However, NSCLC tumors almost inevitably acquire resistance EGFR-TKIs, limiting drug efficacy. Previous studies suggested co-localization c-MET may possible...
Abstract Erdheim Chester Disease (ECD) is a rare, non-Langerhans cell histiocytic disease, characterized as neoplastic disorder in 2016. MAP Kinase and PI3-AKT pathway somatic mutations and/or fusion genes have been shown to play significant role disease pathogenesis. Despite this, molecular sequencing at diagnosis has yet become standard of practice. Retrospective analysis 19 patients diagnosed with ECD single institution over twenty-years (2002-2022) was conducted. Inclusion criteria were...
4529 Background: Oncology patients experience more severe disease outcomes from COVID-19 infection than the general population. BCG is a live bovine tuberculosis bacillus with immunotherapeutic effects in urothelial cancers; it also used as vaccination against Mycobacterium parts of world. As has been associated broad protection viral pathogens, exposure through or intravesical therapy may modulate host immunity and reduce severity infection. We report effect on oncology CCC19 registry....